Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd
Your view on CU6.AX
Overview
What the company does, where it operates, and who runs it.
About Clarity Pharmaceuticals Ltd
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Michelle Parker
- Headquarters
- National Innovation Centre, Sydney, NSW, AU
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Michelle Parker
- Headquarters
- National Innovation Centre, Sydney, NSW, AU
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.
It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer.
The company was incorporated in 2010 and is based in Sydney, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Clarity Pharmaceuticals Ltd. Starting points for Clarity Pharmaceuticals Ltd: EPS -AUD 0.29, beta 1.18 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Clarity Pharmaceuticals Ltd. Clarity Pharmaceuticals Ltd does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Clarity Pharmaceuticals Ltd. Trailing twelve-month EPS for Clarity Pharmaceuticals Ltd stands at -AUD 0.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterMar 2023 | Next quarterDec 2024 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | −AUD 0.07 | −AUD 0.31 | −AUD 0.30 |
| Lowest estimate | AUD 0.00 | −AUD 0.07 | −AUD 0.40 | −AUD 0.45 |
| Highest estimate | AUD 0.00 | −AUD 0.07 | −AUD 0.23 | −AUD 0.06 |
| Number of analysts | 0 | 1 | 5 | 5 |
| A year ago | — | — | −AUD 0.291 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterMar 2023 | Next quarterDec 2024 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 6.55M | AUD 5.92M | AUD 16.00M | AUD 32.97M |
| Lowest estimate | AUD 6.55M | AUD 5.92M | AUD 3.03M | AUD 6.25M |
| Highest estimate | AUD 6.55M | AUD 5.92M | AUD 29.62M | AUD 61.04M |
| Number of analysts | 2 | 1 | 4 | 4 |
| A year ago | — | — | AUD 0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Clarity Pharmaceuticals Ltd. Clarity Pharmaceuticals Ltd has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| CYC.AXCyclopharm Limited | Healthcare | Medical - Devices | — | ||
| RAD.AXRadiopharm Theranostics Limited | Healthcare | Biotechnology | — | ||
| TLX.AXTelix Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ANIKAnika Therapeutics, Inc. | Healthcare | NASDAQ | $177.2M | ||
| APYXApyx Medical Corporation | Healthcare | NASDAQ | $101.1M | ||
| ASFXAmerican Scientific Resources, Incorporated | Healthcare | OTC | $7,001 | ||
| AVTIAvitar, Inc. | Healthcare | OTC | $1,382 | ||
| BEATHeartBeam, Inc. | Healthcare | NASDAQ | $17.4M | ||
| BEATWHeartBeam, Inc. | Healthcare | NASDAQ | $6.6M | ||
| BIELBioElectronics Corporation | Healthcare | OTC | $7.2M | ||
| BMGPBiomagnetics Diagnostics Corp. | Healthcare | OTC | $1,265 | ||
| BRSYFBrainsWay Ltd. | Healthcare | OTC | $451.7M | ||
| BTTXBetter Therapeutics, Inc. | Healthcare | OTC | $5,452 | ||
| BWAYBrainsWay Ltd. | Healthcare | NASDAQ | $332.6M | ||
| CPYTCarePayment Technologies, Inc. | Healthcare | OTC | $1,667 | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| IEFAiShares Core MSCI EAFE ETF | $188.8B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.01% | |
| GWXState Street SPDR S&P International Small Cap ETF | $882M in assets | 0.03% | |
| IPACiShares Core MSCI Pacific ETF | $2.6B in assets | 0.00% | |
| VIU.TOVanguard FTSE Developed All Cap ex North America Index ETF | $11.4B in assets | 0.00% | |
| VSGXVanguard ESG International Stock ETF | $6.7B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in CU6.AX.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Clarity Pharmaceuticals Ltd.